These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 19295310)

  • 1. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab.
    Beimler JH; Morath C; Schmidt J; Ovens J; Opelz G; Rahmel A; Zeier M; Süsal C
    Transplantation; 2009 Mar; 87(5):668-71. PubMed ID: 19295310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of a positive flow crossmatch on the outcomes of cadaveric renal transplants.
    Ilham MA; Winkler S; Coates E; Rizzello A; Rees TJ; Asderakis A
    Transplant Proc; 2008; 40(6):1839-43. PubMed ID: 18675065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
    Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
    Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrative approach for the transplantation of high-risk sensitized patients.
    Morath C; Beimler J; Opelz G; Ovens J; Scherer S; Schmidt J; Schmied B; Gross ML; Schwenger V; Zeier M; Süsal C
    Transplantation; 2010 Sep; 90(6):645-53. PubMed ID: 20671598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation.
    Bingaman AW; Murphey CL; Palma-Vargas J; Wright F
    Transplantation; 2008 Dec; 86(12):1864-8. PubMed ID: 19104435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
    Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
    Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody.
    Higgins R; Hathaway M; Lowe D; Lam F; Kashi H; Tan LC; Imray C; Fletcher S; Zehnder D; Chen K; Krishnan N; Hamer R; Briggs D
    Transplantation; 2007 Oct; 84(7):876-84. PubMed ID: 17984841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hidden perils in a highly sensitized kidney transplant recipient.
    Ford S; Summers S; Cantwell L; Mulley W
    Nephrology (Carlton); 2012 Apr; 17 Suppl 1():9-11. PubMed ID: 22497647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up.
    Lachmann N; Terasaki PI; Schönemann C
    Clin Transpl; 2006; ():171-99. PubMed ID: 18365377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch.
    Higgins R; Lowe D; Hathaway M; Williams C; Lam FT; Kashi H; Tan LC; Imray C; Fletcher S; Chen K; Krishnan N; Hamer R; Daga S; Edey M; Zehnder D; Briggs D
    Transplantation; 2011 Oct; 92(8):900-6. PubMed ID: 21968524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
    Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
    Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations.
    Amico P; Hirt-Minkowski P; Hönger G; Gürke L; Mihatsch MJ; Steiger J; Hopfer H; Schaub S
    Transpl Int; 2011 Jun; 24(6):560-9. PubMed ID: 21332582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.